Cite
NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
MLA
O’Brien, Christopher F., et al. “NBI-98854, a Selective Monoamine Transport Inhibitor for the Treatment of Tardive Dyskinesia: A Randomized, Double-Blind, Placebo-Controlled Study.” Movement Disorders, vol. 30, no. 12, Oct. 2015, pp. 1681–87. EBSCOhost, https://doi.org/10.1002/mds.26330.
APA
O’Brien, C. F., Jimenez, R., Hauser, R. A., Factor, S. A., Burke, J., Mandri, D., & Castro, G. J. C. (2015). NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Movement Disorders, 30(12), 1681–1687. https://doi.org/10.1002/mds.26330
Chicago
O’Brien, Christopher F., Roland Jimenez, Robert A. Hauser, Stewart A. Factor, Joshua Burke, Daniel Mandri, and Gayol, Julio C. Castro. 2015. “NBI-98854, a Selective Monoamine Transport Inhibitor for the Treatment of Tardive Dyskinesia: A Randomized, Double-Blind, Placebo-Controlled Study.” Movement Disorders 30 (12): 1681–87. doi:10.1002/mds.26330.